查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1138415

先兆子癇診斷的全球市場-2022-2029

Global Preeclampsia Diagnostics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場動態

先兆子癇的發病率在全球範圍內呈上升趨勢。對其診斷和治療的需求激增預計將推動先兆子癇診斷市場的增長。

預計對其診斷和治療的需求激增將推動市場增長。

對其診斷和治療的需求激增預計將推動先兆子癇診斷市場的增長。根據先兆子癇基金會的數據，全世界每年有超過 1000 萬女性患上先兆子癇，先兆子癇每年導致約 250 萬例早產。這種疾病影響發達國家和發展中國家的新生兒和母親。根據世界衛生組織（WHO）的數據，發展中國家先兆子癇的患病率是發達國家的七倍。此外，BioMed Central (BMC) 報告稱，新興經濟體中先兆子癇的發病率在 1.8% 至 16.7% 之間。非洲大陸約有 10% 的孕婦患有這種疾病。孕產婦和圍產期死亡率和發病率的上升預計將增加對孕婦先兆子癇早期診斷的需求。

此外，增加對用於檢測指示先兆子癇的生物標誌物的創新測試的研發預計將在預測期內促進市場增長。例如，2022 年 11 月，都柏林圓形醫院 RCSI 婦產科的一個研究小組在 2022 年世界糖尿病日之前啟動了三項研究，調查女性患糖尿病的經歷和影響。這三項研究由地區衛生研究委員會 (HRB) 和歐盟委員會資助，總額為 110 萬歐元。愛爾蘭試驗將檢驗阿司匹林在改善糖尿病孕婦健康方面的作用。這是第一項研究低劑量阿司匹林對預防糖尿病女性先兆子癇（妊娠期高血壓）影響的試驗。

2020 年 7 月，赫爾辛基大學的研究人員發現，HLA-G 基因調節出生時的性別比例。這項研究強化了先前的發現，即男性胎兒易患先兆子癇。

預計新興國家缺乏對先兆子癇的認識將阻礙市場增長。

由於醫療保健專業人員對這種情況的有效篩查工具缺乏認識，以及準媽媽對與先兆子癇相關的體徵和症狀的了解越來越多，這可能會促進先兆子癇的發展診斷市場在預測期內迅速發展。

行業分析

全球先兆子癇診斷市場根據各種行業因素（包括波特五力、監管和報銷分析、價值鏈分析、定價分析、技術進步、流行病學等）對市場進行深入分析。

全球先兆子癇診斷市場報告提供大約 45 多個市場數據表、40 多個數字和 180 頁內容。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

  • 按產品類型劃分的市場細分
  • 按測試類型劃分的市場細分
  • 最終用戶的市場細分
  • 按地區劃分的市場細分

第 4 章市場動態

  • 市場影響因素
  • 驅動程序
    • 先兆子癇患病率上升
    • 先兆子癇診斷的技術進步
  • 限制
    • 新興國家缺乏對先兆子癇的認識
  • 商機
  • 影響分析

第五章行業分析

  • 波特五力分析
  • 流行病學
  • 供應鏈分析
  • 定價分析
  • 法律法規分析
  • 技術進步
  • 未滿足的需求

第 6 章按產品類型分析

  • 設備
  • 消耗品

第 7 章按測試類型

  • 驗血
  • 尿液分析

第 8 章最終用戶

  • 醫院
  • 診斷中心
  • 專科診所
  • 其他

第 9 章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 10 章競爭格局

  • 競爭場景
  • 市場定位/市場份額分析
  • 併購分析

第 11 章公司簡介

  • Diabetomics, Inc.
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Thermo Fisher Scientific Inc.
  • F. Hoffmann-La Roche Ltd
  • PerkinElmer Inc.
  • Siemens Healthineers AG
  • DRG INSTRUMENTS GMBH
  • Metabolomic Diagnostics Ltd.
  • Bayer AG
  • Sera Prognostics（*List is not exhaustive）

第12章 DataM

簡介目錄
Product Code: DMMD2588

Market Overview

Preeclampsia Diagnostics Market size was valued US$ 1.03 billion in 2021 and is estimated to reach US$ 1.24 billion by 2029, growing at a CAGR of 11.0% during the forecast period (2022-2029).

Preeclampsia is a major cause of illness and deaths among mothers and their babies globally. It is characterized by elevated blood pressure and excessive protein in the urine of pregnant women which can cause the baby delivered preterm and smaller than usual. This severe pregnancy disorder occurs in up to 5% of all pregnancies. It is one of the leading hypertensive disorders of pregnancy across the developed and emerging countries. If it is not diagnosed at an early stage, then it may lead to preterm birth and other complications, such as failure of organs, seizure or eclampsia, and death. For instance, according to the Preeclampsia Foundation, it has been estimated that pregnancy-induced hypertension is responsible for causing 76,000 maternal and 500,000 infant deaths each year globally.

Market Dynamics

The rising incidences of preeclampsia globally. The rapidly growing demand for its diagnosis and treatment is expected to drive the growth of preeclampsia diagnostics market.

Rapidly growing demand for its diagnosis and treatments are expected to drive market growth.

The rapidly growing demand for its diagnosis and treatment is expected to drive the growth of preeclampsia diagnostics market. According to the Preeclampsia Foundation, more than 10 million women globally develop preeclampsia every year, and around 2.5 million preterm birth are caused by preeclampsia annually. The disorder is affecting both neonates and mothers in developed and developing nations. According to the World Health Organization (WHO), the prevalence of preeclampsia is seven times higher in emerging countries as compared to developed countries. Also, as per a report by BioMed Central (BMC), the incidence of preeclampsia ranges from 1.8% to 16.7% in developing economies. It affects around 10% of pregnant women in the African continent. The rise in maternal & perinatal mortality and morbidity rates is projected to increase the demand for early diagnosis of preeclampsia among pregnant women.

In addition, increasing research and development to innovative new tests to detect biomarkers indicating preeclampsia is expected to boost the market growth over the forecast period. For instance, in November 2022, a team of researchers at the RCSI Department of Obstetrics and Gynaecology at the Rotunda Hospital, Dublin launched three research studies that examined the experiences and impact of diabetes in women, ahead of World Diabetes Day 2022. The three studies have been awarded total funding of €1.1 million in this region by the Health Research Board (HRB) and the European Commission. The IRELAnD Trial will examine the role that aspirin improves the health of pregnant women with diabetes. This is the first study to examine the impact of low-dose aspirin for the prevention of preeclampsia (high blood pressure during pregnancy) in women with diabetes.

Also in July 2020, researchers from the University of Helsinki have shown that HLA-G gene regulates the male-to-female ratio at birth. The study strengthens earlier findings of the vulnerability of male fetuses to preeclampsia.

Lack of awareness about Preeclampsia in developing countries is expected to hamper the market growth.

The lack of awareness about the effective screening tools for the condition among the healthcare providers and increasing knowledge about the signs & symptoms associated with preeclampsia among pregnant mothers and are likely to boost the preeclampsia diagnostics market growth rapidly over the forecast period.

Industry Analysis

The global preeclampsia diagnostics Market provides in-depth analysis of the market based on various industry factors such as Porter's Five Forces, Regulatory & Reimbursement Analysis, Value Chain Analysis, Pricing Analysis, Technological Advancements, Epidemiology etc.

Segment Analysis

Blood tests segment is expected to hold the largest market share in global preeclampsia diagnostics market

The blood tests accounted for the largest market share of the preeclampsia diagnostics market in 2022, owing to the several advantages of blood tests in detecting the biomarkers efficiently which are responsible for preeclampsia. Several organizations are highly adopting blood tests as a better test for the detection of preeclampsia. With advancements in technology, new tests are being introduced in the market, which are further boosting the blood test market growth. For instance, the NHS England approved two blood test products named Elecsys sFlt-1 and PlGF immunoassays of F. Hoffmann-La Roche under the 'Innovation and Technology Payment' program in June 2022. The NHS aims to implement the usage of innovative products within the hospitals in Europe and enhance the accessibility of diagnostic tools for preeclampsia among healthcare professionals to detect pregnancy-induced hypertension.

Geographical Analysis

North America region holds the largest market share in the global preeclampsia diagnostics market

North America region is dominating the global preeclampsia diagnostics market accounting for the largest market share in 2022, owing to the increasing healthcare expenditure, adoption of highly advanced products, growing awareness towards preeclampsia among the patients and healthcare providers regarding the severity of the condition. The increasing prevalence of preeclampsia is leading to an increase in medical treatment cost among women with preeclampsia and their newborns. For instance, according to the American Journal of Obstetrics and Gynecology (AJOG), the total cost of maternal healthcare with preeclampsia was around one-third of the total U.S. healthcare costs of women with preeclampsia.

Competitive Landscape

The Preeclampsia Diagnostics market is dominated by major players including Diabetomics, Inc., Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd, PerkinElmer Inc., Siemens Healthineers AG, DRG Instruments GMBH, Metabolomic Diagnostics Ltd., Bayer AG, Sera Prognostics, among others.

Global Preeclampsia Diagnostics Market - Key Companies to Watch

F. Hoffmann-La Roche Ltd

Overview: Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is one of the largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology, and neuroscience. Roche is global leader in in vitro diagnostics and tissue-based cancer diagnostics, and a front runner in diabetes management.

Product Portfolio: Elecsys sFlt-1/PlGF- immunoassays for preeclampsia are the first available and approved automated diagnostic tests for fast and easy assessment in a clinical conext.

The global preeclampsia diagnostics market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Product type
  • 3.2. Market Snippet by Test Type
  • 3.3. Market Snippet by End-User
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
  • 4.2. Drivers
    • 4.2.1. Rising Prevalence of Preeclampsia
    • 4.2.2. Technological Advancements in Preeclampsia Diagnostic
  • 4.3. Restraints:
    • 4.3.1. Lack of awareness about Preeclampsia in developing countries
  • 4.4. Opportunity
  • 4.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Epidemiology
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Regulatory Analysis
  • 5.6. Technological Advancements
  • 5.7. Unmet Needs

6. By Product Type

  • 6.1. Introduction
  • 6.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type Segment.
  • 6.3. Market Attractiveness Index, By Product Type Segment
    • 6.3.1. Instruments*
      • 6.3.1.1. Introduction
      • 6.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 6.3.2. Consumables

7. By Test Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type Segment.
    • 7.1.2. Market Attractiveness Index, By Test Type Segment
  • 7.2. Blood Tests*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 7.3. Urine Analysis

8. By End-User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User Segment.
    • 8.1.2. Market Attractiveness Index, By End-User Segment
  • 8.2. Hospitals*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
  • 8.3. Diagnostic Centers
  • 8.4. Specialty Clinics
  • 8.5. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. The U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. The U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Italy
      • 9.3.6.5. Spain
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. Australia
      • 9.5.6.5. Rest of Asia Pacific
  • 9.6. The Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Diabetomics, Inc.*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Thermo Fisher Scientific Inc.
  • 11.3. F. Hoffmann-La Roche Ltd
  • 11.4. PerkinElmer Inc.
  • 11.5. Siemens Healthineers AG
  • 11.6. DRG INSTRUMENTS GMBH
  • 11.7. Metabolomic Diagnostics Ltd.
  • 11.8. Bayer AG
  • 11.9. Sera Prognostics (*List is not exhaustive)

12. DataM Intelligence

  • 12.1. Appendix
  • 12.2. About Us and Services
  • 12.3. Contact Us